Meropenem Accordpharma

Meropenem, the active ingredient in Meropenem Accordpharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, respiratory and central nervous system infections.

GNH USA supplies Meropenem Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by Gram‑negative and Gram‑positive bacteria.

- Complicated intra‑abdominal infections: provides bactericidal activity to resolve infection. - Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary sterility. - Hospital‑acquired pneumonia: achieves rapid bacterial clearance in ventilated patients. - Ventilator‑associated pneumonia: targets multidrug‑resistant organisms in the lower respiratory tract. - Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. - Sepsis: delivers systemic bactericidal effect to control bloodstream infection.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis after infusion. - Headache: transient headache during or after dosing. - Rash: mild erythematous skin reactions. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity requiring immediate intervention. - Clostridioides difficile infection: severe colitis secondary to gut flora disruption. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Meropenem should be used with careful clinical assessment and monitoring. - Assess renal function: adjust dose in patients with impaired clearance. - Monitor for seizures: avoid in patients with a history of epilepsy or CNS disease. - Review antibiotic susceptibility: use only when the pathogen is proven or highly suspected to be susceptible. - Observe for allergic reactions: discontinue if signs of anaphylaxis appear. - Evaluate hepatic status: monitor liver enzymes during prolonged therapy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several drugs that affect its efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity. - Aminoglycosides: combined nephrotoxic potential warrants avoidance.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate renal impairment, requiring dose adjustment. - Warfarin: occasional alteration of INR, necessitating closer coagulation monitoring. - Oral contraceptives: possible reduction in hormonal efficacy, advise alternative contraception.